Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refractory to conventional therapies [VALUTAZIONE DELL'EFFICACIA DEL TRATTAMENTO ASSOCIATO [90Y-DOTA, TYR(3)]OCTREOTATE E [177Lu-DOTA, TYR(3)]OCTREOTATE, IN PAZIENTI CON NEOPLASIE NEUROENDOCRINE ESPRIMENTI RECETTORI PER LA SOMATOSTATINA REFRATTARIE AI TRATTAMENTI CONVENZIONALI].
Latest Information Update: 10 Oct 2013
At a glance
- Drugs 90Y DOTATATE (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 10 Oct 2013 New trial record